Venus Concept Inc. (VERO): Price and Financial Metrics
GET POWR RATINGS... FREE!
VERO Stock Summary
- VERO has a market capitalization of $90,878,642 -- more than approximately only 14.06% of US stocks.
- VERO's went public 4.47 years ago, making it older than merely 16.65% of listed US stocks we're tracking.
- In terms of volatility of its share price, VERO is more volatile than 80.96% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Venus Concept Inc, a group of peers worth examining would be TNC, MNTX, ANY, ISDR, and ZCMD.
- VERO's SEC filings can be seen here. And to visit Venus Concept Inc's official web site, go to www.venusconcept.com.
VERO Valuation Summary
- In comparison to the median Healthcare stock, VERO's price/sales ratio is 88.55% lower, now standing at 1.3.
- VERO's price/sales ratio has moved down 12.5 over the prior 47 months.
- Over the past 47 months, VERO's price/earnings ratio has gone up 9.2.
Below are key valuation metrics over time for VERO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VERO | 2021-08-31 | 1.3 | 3.2 | -4.0 | -7.8 |
| VERO | 2021-08-30 | 1.3 | 3.1 | -3.9 | -7.7 |
| VERO | 2021-08-27 | 1.3 | 3.1 | -3.9 | -7.7 |
| VERO | 2021-08-26 | 1.2 | 2.9 | -3.7 | -7.3 |
| VERO | 2021-08-25 | 1.2 | 3.0 | -3.8 | -7.5 |
| VERO | 2021-08-24 | 1.2 | 2.9 | -3.7 | -7.3 |
VERO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VERO has a Quality Grade of C, ranking ahead of 56.31% of graded US stocks.
- VERO's asset turnover comes in at 0.629 -- ranking 64th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows VERO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.629 | 0.676 | -0.148 |
| 2021-03-31 | 0.567 | 0.666 | -0.233 |
| 2020-12-31 | 0.508 | 0.659 | -0.503 |
| 2020-09-30 | 0.937 | 0.703 | -0.500 |
| 2020-06-30 | 1.031 | 0.701 | -0.667 |
| 2020-03-31 | 1.225 | 0.694 | -0.875 |
VERO Price Target
For more insight on analysts targets of VERO, see our VERO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.55 | Average Broker Recommendation | 1.3 (Strong Buy) |
VERO Stock Price Chart Interactive Chart >
VERO Price/Volume Stats
| Current price | $0.76 | 52-week high | $3.37 |
| Prev. close | $0.72 | 52-week low | $0.62 |
| Day low | $0.68 | Volume | 225,874 |
| Day high | $0.80 | Avg. volume | 214,497 |
| 50-day MA | $1.08 | Dividend yield | N/A |
| 200-day MA | $1.62 | Market Cap | 48.88M |
Venus Concept Inc. (VERO) Company Bio
Venus Concept Inc. (formerly Restoration Robotics, Inc.), a medical device company, develops and commercializes image-guided robotic systems in the United States and internationally. It offers ARTAS System, a physician-assisted robotic system that identifies and dissects hair follicular units directly from the scalp and creates recipient implant sites. The company was founded in 2002 and is based in San Jose, California.
Latest VERO News From Around the Web
Below are the latest news stories about Venus Concept Inc that investors may wish to consider to help them evaluate VERO as an investment opportunity.
Analysts Expect Breakeven For Venus Concept Inc. (NASDAQ:VERO) Before LongVenus Concept Inc. ( NASDAQ:VERO ) is possibly approaching a major achievement in its business, so we would like to... |
Venus Concept Inc. to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16thTORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Management will participate in a virtual fireside chat at the conference on Wednesday, February 16th at 11:00 a.m. Eastern Time. A webcast of the fireside chat will be available to BTIG clients attending |
Venus Concept to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 28, 2022TORONTO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Monday, March 28, 2022. Management will host a conference call at 8:00 a.m. Eastern Time on March 28, 2022 to discuss the results of the quarter and fiscal year with a question and answer session. Those who would like to p |
Venus Concept gets FDA nod to market BlissMAX deviceVenus Concept (VERO) has won FDA 510(k) clearance to market its Venus BlissMAX device in the U.S.BlissMAX is a medical aesthetic platform that serves as a comprehensive solution for |
BTIG Remains a Buy on Venus Concept (VERO)In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Venus Concept (VERO – Research Report), with a price target of $7.00. The company's shares closed last Tuesday at $1.73. According to TipRanks.com, Thibault is a 5-star analyst with an average return of 26.5% and a 39.6% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Venus Concept with a $5.00 average price target. |
VERO Price Returns
| 1-mo | -23.07% |
| 3-mo | -51.90% |
| 6-mo | -44.53% |
| 1-year | -63.46% |
| 3-year | -99.42% |
| 5-year | N/A |
| YTD | -55.29% |
| 2021 | -1.73% |
| 2020 | -63.19% |
| 2019 | -95.25% |
| 2018 | -90.43% |
| 2017 | N/A |
Loading social stream, please wait...